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We have read the comments by Wydra and Romanowicz with
great interest. We agree with them, that the difference in detection
rates between the protocols (one day and two day protocols) found
in our study [1] could be related to the timing.
We start our procedures with Nanocoll tracer, when we have
performed two day protocols, and then we continue with Sentis-
cint. We have also changed our protocol on one day one. That is
why the choice of radiocolloids for patients with various FIGO stag-
es was accidental and it was a consequence of these facts. Spe-
cifically, in 1 patient with FIGO stage IA1 we used Nanocoll (two-
day protocol), in 2 patients with IA2 Nanocoll (two day protocol)
and in 30 patients with IB1: in 8 patients Nanocoll (1 one-day pro-
tocol, 7 two-day protocols), in 1 Nanocis (two-day protocol), in 21
pts Sentiscint (3 two-day protocols and 18 one-day protocols), in
2 pts with IB2 Sentiscint (1 one-day and 1 two-day protocols), in
one patient with IIIA Sentiscint  one-day protocol, in 18 patients
with IIIB: 11 patients Sentiscint (2 two-day and 9 one-day proto-
cols) and 7 patients Nanocoll (two-day protocols).
We agree that FIGO stage III would not normally be selected
for sentinel lymph node detection and biopsy because of its ad-
vanced stage, but our indication for surgery and SLN biopsy is
done on the basis of clinical staging. However, in our study, final
surgical and histopathological staging have differed from clinical
staging by up to 40%. All examined patients have been incorpo-
rated in the study including those with advanced stage cancer.
In our other study we had 63 patients with early stage cervical
cancer (stage FIGO IA2IIA). By combining patent blue dye and
radiocolloid, SLN was detected in 59 patients (93.6%), from which
49 patients (78%) were bilateral and 10 patients (16%) were uni-
lateral. In 4 patients (6%) SLN detection was not successful.
Detection rate of SLN was dependent on tumour size. With
larger tumour size, detection success was lower. In stage FIGO
IB2 (tumour size above 4 centimetres) detection was only 50%.
This was caused by more difficult radiocolloid injection into the
cervix, by present necrosis and by the fact that these patients had
had neoadjuvant chemotherapy before surgery.
Detection success of SLN is also dependent on the FIGO stage
 the higher stages had lower detection rates (however, stage
IIA with vaginal spread did not have worse detection success of
SLN than stage IB2). Patients age, histopathological tumour dif-
ferentiation or previous conisation did not have an influence on
the detection rate. The relation between histopathological tumour
type and SLN detection success has not been possible to assess
as a result of the small number of our patients.
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